Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy

Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve 2020-12, Vol.62 (6), p.705-709
Main Authors: Rogers, Amanda B., Zaidman, Craig M., Connolly, Anne M.
Format: Article
Language:English
Subjects:
Administration, Oral
Adolescent
Adrenal Cortex Hormones - administration & dosage
Child
Child, Preschool
Children
CIDP
Corticoids
Corticosteroids
Demography
Demyelination
Duration of Therapy
Female
Glucocorticoids - administration & dosage
Health services
Humans
Immunoglobulins, Intravenous - therapeutic use
Immunologic Factors - therapeutic use
Immunomodulation
immunomodulatory therapy
Infant
Inflammation
inflammatory neuropathy
Irritable Mood
Maintenance
Maintenance Chemotherapy
Male
Medical records
Medical treatment
Patients
pediatric CIDP
Pediatrics
Polyneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology
Prednisone - administration & dosage
Pulse Therapy, Drug
Side effects
Sleep Initiation and Maintenance Disorders - chemically induced
Therapy
Weight Gain
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long‐term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high‐dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow‐up. Here, we describe the demographics, disease course, treatment regimens, and long‐term outcomes of these patients. Twenty‐five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow‐up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long‐term treatment option in children with CIDP.
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.27058